Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptIMMize-2 long-term extension of risankizumab in pediatric plaque psoriasis (Japan)
jRCT2041220091Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc. Primary endpoint: Number of Participants With Adverse Events. Started Nov 2022; status: recruiting.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2041220091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220091.